NQO1 and familial pancreatic carcinoma: Moreover, intrinsic or accumulated drug resistance rapidly makes these agents ineffective and severely limits the therapeutic window33. Elevated NQO1 overexpression in a variety of solid tumors, including pancreatic cancer, has emerged as an effective tumor-selective target3–6.